Association between use of lubiprostone and headache: A systematic review and meta‐analysis of randomized controlled trials
- 2 October 2025
- journal article
- review article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 91 (12) , 3315-3322
Abstract
Aims: Lubiprostone and its active metabolite may activate prostaglandin receptors, raising concerns about an increased risk of headache. We performed a systematic review and meta‐analysis to identify whether lubiprostone increases the risk of headache. Methods: To identify all relevant randomized controlled trials (RCTs), we comprehensively searched MEDLINE (via PubMed), ClinicalTrials.gov website and the Cochrane Central Register of Controlled Trials. The search focused on studies comparing lubiprostone vs . placebo or other laxatives. A DerSimonian–Laird random‐effects model was utilized to estimate risk ratios (RRs) and 95% confidence intervals (CIs). A fixed‐effect method based on the Mantel–Haenszel method was employed for analyses with 3 or fewer studies. Heterogeneity was assessed using the I 2 statistic, and the certainty of evidence was rated using the GRADE approach. Results: Twenty‐six studies were examined in the analysis. The incidence of headache was 5.3% for lubiprostone and 3.2% for placebo or other laxatives. Lubiprostone increased the risk of headache (RR 1.32, 95% CI 1.02–1.71, I 2 = 0%, 6265 patients, 26 RCTs, moderate certainty) relative to placebo or other laxatives. The risk of headache seemed to be consistently increased in both adults (RR 1.23, 95% CI 0.93–1.62, I 2 = 0%, 5390 patients, 24 RCTs, moderate certainty) and children (RR 3.07, 95% CI 1.67–5.63, I 2 = 84.4%, 875 patients, 2 RCTs, very low certainty). Conclusion: The results of this meta‐analysis suggest that lubiprostone treatment increases the risk of headache in adults.Keywords
This publication has 23 references indexed in Scilit:
- Efficacy of lubiprostone for functional constipation treatment in adolescents and children: Randomized controlled trialJournal of Pediatric Gastroenterology and Nutrition, 2024
- Lubiprostone for Pediatric Functional Constipation: Randomized, Controlled, Double-Blind Study With Long-term ExtensionClinical Gastroenterology and Hepatology, 2022
- Human models of migraine — short-term pain for long-term gainNature Reviews Neurology, 2017
- A Randomized, Double-Blind, Placebo-Controlled Trial to Examine the Effectiveness of Lubiprostone on Constipation Symptoms and Colon Transit Time in Diabetic PatientsAmerican Journal of Gastroenterology, 2017
- A Randomized, Placebo-Controlled Trial of Lubiprostone for Opioid-Induced Constipation in Chronic Noncancer PainAmerican Journal of Gastroenterology, 2015
- Lubiprostone Plus PEG Electrolytes Versus Placebo Plus PEG Electrolytes for Outpatient Colonoscopy PreparationAmerican Journal of Therapeutics, 2015
- Lubiprostone Increases Spontaneous Bowel Movement Frequency and Quality of Life in Patients With Chronic Idiopathic ConstipationClinical Gastroenterology and Hepatology, 2015
- Prostaglandin E2 receptor expression in the rat trigeminal-vascular system and other brain structures involved in painNeuroscience Letters, 2012
- Lubiprostone neither decreases gastric and small-bowel transit time nor improves visualization of small bowel for capsule endoscopy: a double-blind, placebo-controlled studyGastrointestinal Endoscopy, 2009
- Activation of prostaglandin EP receptors by lubiprostone in rat and human stomach and colonBritish Journal of Pharmacology, 2008